Monitor enrollment progress and any interim data releases; the primary endpoint readout (rTNSS at 14 days) is the next major catalyst. No financial guidance or revenue impact is yet available.
Price Chart
Executive Summary
Polyrizon announced the enrollment of the first patient in its U.S. clinical study for NASARIX (PL-14), an investigational drug-free hydrogel nasal spray for seasonal allergic rhinitis. This milestone transitions the company from preclinical to clinical-stage development, with a 120-patient randomized study underway at 5 U.S. sites. The event is a significant operational catalyst but lacks financial data or a binary near-term readout, tempering immediate stock impact.
Key Facts
- First patient enrolled in U.S. clinical study for NASARIX (PL-14) Allergy Blocker in seasonal allergic rhinitis.
- Study is prospective, multicenter, randomized, single-blind, two-arm, targeting 120 patients at 5 U.S. sites.
- Primary endpoint: difference in mean daily reflective Total Nasal Symptom Score (rTNSS) over first 14 treatment days.
- NASARIX is a non-pharmacological, drug-free mucoadhesive hydrogel nasal spray forming a physical barrier.
- This marks Polyrizon's transition into a clinical-stage company.
Financial Impact
No financial data provided; study costs and potential market size not disclosed.
Risk Factors
- Clinical trial may fail to meet primary endpoint, leading to stock decline.
- Enrollment delays or safety issues could derail timeline.
- Competing allergy treatments (pharmacological and device-based) may limit commercial potential.
- Company is early-stage with no approved products or revenue.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $9.01 | awaiting T+1 | — | $8.58 (−4.77%) |
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | — | $8.58 (−4.77%) |
Oct 5, 2026 22d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.58 (−11.27%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.58 (+10.72%) |
Sep 22, 2026 5w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.58 (−19.51%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.58 (+21.28%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.58 (−16.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers